Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 9/20 | 0.55 |
| ▸ | CDK2 | P24941 | 9/20 | 0.55 |
| ▸ | CCNA1 | P78396 | 9/20 | 0.55 |
| ▸ | AURKA | O14965 | 7/20 | 0.55 |
| ▸ | EP300 | Q09472 | 4/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 4/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | USP7 | Q93009 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4019871 | 0.89 | CCNA2 (0.47) | CCNA2CDK2CCNA1AURKAEP300 | |
| SCHEMBL4017924 | 0.86 | CCNA2 (0.43) | CCNA2CDK2CCNA1AURKAEP300 | |
| SCHEMBL2915619 | 0.72 | CCNA2 (0.50) | CCNA2CDK2CCNA1AURKAEP300 | |
| SCHEMBL5720875 | 0.72 | CCNA2 (0.55) | CCNA2CDK2CCNA1AURKAEP300 | |
| SCHEMBL2921269 | 0.71 | AURKA (1.00) | CCNA2CDK2CCNA1AURKAEP300 | |
| SCHEMBL5720802 | 0.71 | BRD4 (0.62) | CCNA2CDK2CCNA1AURKAEP300 | |
| SCHEMBL2918932 | 0.66 | AURKA (0.77) | CCNA2CDK2CCNA1AURKAEP300 | |
| SCHEMBL2919441 | 0.66 | CCNA2 (0.72) | CCNA2CDK2CCNA1AURKAEP300 | |
| SCHEMBL17232769 | 0.66 | CCNA2 (0.53) | CCNA2CDK2CCNA1AURKAEP300 | |
| SCHEMBL2919788 | 0.65 | AURKA (0.77) | CCNA2CDK2CCNA1AURKAEP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531531-B2 | Method of treating diseases associated with altered kinase activity with bicyclo-pyrazoles | PFIZER ITALIA S.R.L. (IT) | 2009-05-12 | — | — | US | disclosed |
| US-20070191386-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191386-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K20, MAP3K19, MAP3K1 | CCNA2 848/4885CDK2 43/4885CCNA1 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.